Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5904.074 | 0.0286 | -0.9497 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5904.074 | 0.0286 | -0.9497 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 5904.074 | 0.0215 | -0.9625 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 5904.074 | 0.0215 | -0.9625 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14821.203 | 1.0119 | 1.0205 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14821.203 | 1.0119 | 1.0205 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14821.203 | 0.9807 | 0.9666 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14821.203 | 0.9807 | 0.9666 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14821.203 | 0.9134 | 0.8491 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14821.203 | 0.9134 | 0.8491 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14821.203 | 0.2618 | -0.3736 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14821.203 | 0.2618 | -0.3736 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14821.203 | 0.0215 | -0.9281 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14821.203 | 0.0215 | -0.9281 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14821.203 | 0.0142 | -0.9499 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14821.203 | 0.0142 | -0.9499 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14821.203 | 0.0063 | -0.9752 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14821.203 | 0.0063 | -0.9752 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14821.203 | 0.0100 | -0.9630 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14821.203 | 0.0100 | -0.9630 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14821.203 | 0.0111 | -0.9593 | 1.1544 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14821.203 | 0.0111 | -0.9593 | 1.1544 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5905.074 | 1.0083 | 1.0193 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5905.074 | 1.0083 | 1.0193 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5905.074 | 0.9488 | 0.8820 | 0.8648 |